Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Antiparasitic drugs such as anthelmintics, antiporozoals, and others agents are used in the treatment of the parasitic infectious diseases.  According WHO estimation in March 2020, parasitic disease affects 1.5 billion people globally. These diseases include gastrointestinal problems, anemia, wasting, and cognitive and growth deficits in children, and others infections. Among all 1.5 billion people affected with parasitic infectious disease, 24% people are infected with soil-transmitted helminth infections worldwide. Some parasitic infections are life-threatening, while others can cause discomfort in the healthy lifestyle.

The global antiparasitic drugs market was valued at US$ 7,227.9 million in 2019 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020–2027).

Figure 1. Global Antiparasitic Drugs Market Value (US$ Mn) & Y-o-Y Growth Analysis, (2016-2027)

Antiparasitic Drugs  | Coherent Market Insights

The increasing research and development of novel treatments is expected to drive the market growth.

Researchers are focusing on the development of the novel treatments for rare parasitic diseases. For instance, in December 2019, researchers from the University Of Maryland School Of Medicine announced that they have developed a novel treatment for lymphatic filariasis, a disabling parasitic disease that is difficult to treat. The novel treatment has been developed using innovative RNA sequencing techniques. According to the University Of Maryland School Of Medicine, lymphatic filariasis affects over 120 million people worldwide, and it is more prevalent in Asia, Western Pacific, Africa, and parts of the Caribbean and South America. Such factors are driving the growth of the antiparasitic drugs market.

Adverse effects and risks associated with anti-malaria drugs is expected to hamper the global antiparasitic drugs market growth

Most of the antiparasitic drugs cause severe side effects which is expected to hamper demand for these drugs. For instance, Nifurtimox, a drug or the treatment of Chagas’ disease, may not be effective if taken for long courses. Some other disadvantages such as drug resistance, adverse effects, and higher cost of antimalarial drugs such as chloroquine, sulphadoxine/pyrimethamine, mefloquine, and others is expected to hamper the growth of the antiparasitic drugs market.

Global Antiparasitic Drugs Market- Regional Analysis

On the basis of region, the global antiparasitic drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, Africa is expected to hold a dominant position in the market, owing to increasing risk of malaria in the region. For instance, according to the WHO, around 92% of malaria cases in the world occur in Sub-Saharan Africa. In 2017, the WHO also estimated that among the five countries which accounted for nearly half of all malaria cases worldwide, four countries were from Africa region including Nigeria (25%), Democratic Republic of Congo (11%), Mozambique (5%), and Uganda (4%).

In addition to Asia Pacific and Africa, some areas of North America are affected with parasitic infectious diseases. For instance, according to the Centers for Disease Control and Prevention, in 2014, more than 300,000 people in the U.S were infected with Trypanosoma cruzi, the parasite that causes Chagas disease. Moreover, every year, around 300 babies with Trypanosoma Cruzi are born in the U.S. Also, every year, 1,000 hospitalizations for symptomatic cysticercosis occur in the U.S. Furthermore, according to CDC, five neglected parasitic infections (NPIs) including Chagas disease, cysticercosis, toxocariasis, toxoplasmosis, and trichomoniasis are more common in the U.S. Thus, the rising burden of the parasitic infection among the U.S. population is expected to drive growth of the North America antiparasitic drugs market.

Figure 2: Global Antiparasitic Drugs Market Share (%) in Terms of Value, By Region

Antiparasitic Drugs  | Coherent Market Insights

Global Antiparasitic Drugs Market - Competitive Landscape

Key players operating in the global antiparasitic drugs market include Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, Roche Inc., Arbor Pharmaceuticals Inc., Sanofi, AstraZeneca plc., and Alkem Laboratories Limited.

Global Antiparasitic Drugs Market Report Coverage
Report Coverage Details
Base Year: 2019 Market Size in 2019: USD 7,227.9 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.2% 2027 Value Projection: USD 10,842.7 Mn
Geographies covered:
  • North America: U.S.,Canada.
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, UK, Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • Drug Class: Anthelmibtics, Antiprotozoals, Others (Ectoparasites, Pediculocides & miticulocides)
  • Route of Administration: Oral, Injectable, Topical.
  • Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered (11):

Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, Roche Inc., Arbor Pharmaceuticals Inc., Sanofi, AstraZeneca plc., and Alkem Laboratories Limited

Growth Drivers:
  • The increasing number of generic product launches
  • The increasing prevalence of parasitic diseases such as Chagas Disease
  • The increasing government initiatives to provide treatment in low and middle income countries
Restraints & Challenges:
  • Adverse effects of antiparasitic drugs

Parasites are the living organisms found on the host body. There are three type of parasites; protozoa, helminths, and ectoparasites, which can cause parasitic infections in humans. Malaria, Chagas disease, Echinococcosis, Trichomoniasis, Amebiasis, etc., are some of the common parasitic infections affecting the human health. Among these, malaria is considered as a deadly infectious disease affecting the population in both tropical and subtropical regions. Different types of antiparasitic drugs are available in the market for treating such parasitic infections.

Market Dynamics

Malaria, which is caused due to the bite of infected female anopheles mosquito, is considered as a life-threatening infectious disease affecting a large number of people across the world. According to the World Health Organization (WHO), in 2018, around 228 million cases of malaria were diagnosed globally. Moreover, the global death toll due to malaria reached 405,000 in 2018 and an estimated 219 million cases were diagnosed in 2017. Sub-Saharan Africa is the most affected region by malaria and according to WHO estimation, the region accounted for 93% of malaria cases among all the global cases. Thus, the increasing incidence of malaria in the world is expected to drive demand for antimalarial drugs, and thereby drive the growth of the antiparasitic drugs market during the forecast period.

Moreover, various pharmaceutical companies and research institutes are actively participating in research and development of novel drugs for treatment of parasitic infections. For instance, in August 2019, Insud Pharma (in collaboration with Chemo Research S.L.) initiated Phase 3 clinical trial to evaluate the efficacy/safety and population pharmacokinetics of Benznidazole in children with chronic indeterminate Chagas Disease. The study is estimated to complete in March 2027.

Key features of the study:

  • This report provides in-depth analysis of the global antiparasitic drugs market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2020 – 2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global antiparasitic drugs market based on the following parameters: company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study are Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, Roche Inc., Arbor Pharmaceuticals Inc., Sanofi, AstraZeneca plc., and Alkem Laboratories Limited
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
  • The global antiparasitic drugs market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global anti-malarial drugs industry, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Antiparasitic Drugs Market, By Drug Class:
    • Anthelmintics
      • Benzimidazoles
      • Pyrantel
      • Niclosamide
      • Praziquantel
      • Others
    • Antiprotozoals
      • Antimalarial Drugs
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • Other Antiprotozoal Agents
    • Others (Ectoparasites, Pediculocides & miticulocides)
      • Lindane
      • Malathion
      • Pyrethrins
      • Others
  • Global Antiparasitic Drugs Market, By Route of Administration:
    • Oral
    • Injectable
    • Topical
  • Global Antiparasitic Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Antiparasitic Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Anthelmintics
          • Benzimidazoles
          • Pyrantel
          • Niclosamide
          • Praziquantel
          • Others
        • Antiprotozoals
          • Antimalarial Drugs
            • Aminoquinolines
            • Quinoline-methanol (4-quinolinemethanols)
            • Cinchona Alkaloids
            • Biguanides
            • Sulfonamides and sulfones
            • Others
          • Other Antiprotozoal Agents
        • Others (Ectoparasites, Pediculocides & miticulocides)
          • Lindane
          • Malathion
          • Pyrethrins
          • Others
      • By Route of Administration:
        • Oral
        • Injectable
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Anthelmintics
          • Benzimidazoles
          • Pyrantel
          • Niclosamide
          • Praziquantel
          • Others
        • Antiprotozoals
          • Antimalarial Drugs
            • Aminoquinolines
            • Quinoline-methanol (4-quinolinemethanols)
            • Cinchona Alkaloids
            • Biguanides
            • Sulfonamides and sulfones
            • Others
          • Other Antiprotozoal Agents
        • Others (Ectoparasites, Pediculocides & miticulocides)
          • Lindane
          • Malathion
          • Pyrethrins
          • Others
      • By Route of Administration:
        • Oral
        • Injectable
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Anthelmintics
          • Benzimidazoles
          • Pyrantel
          • Niclosamide
          • Praziquantel
          • Others
        • Antiprotozoals
          • Antimalarial Drugs
            • Aminoquinolines
            • Quinoline-methanol (4-quinolinemethanols)
            • Cinchona Alkaloids
            • Biguanides
            • Sulfonamides and sulfones
            • Others
          • Other Antiprotozoal Agents
        • Others (Ectoparasites, Pediculocides & miticulocides)
          • Lindane
          • Malathion
          • Pyrethrins
          • Others
      • By Route of Administration:
        • Oral
        • Injectable
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Anthelmintics
          • Benzimidazoles
          • Pyrantel
          • Niclosamide
          • Praziquantel
          • Others
        • Antiprotozoals
          • Antimalarial Drugs
            • Aminoquinolines
            • Quinoline-methanol (4-quinolinemethanols)
            • Cinchona Alkaloids
            • Biguanides
            • Sulfonamides and sulfones
            • Others
          • Other Antiprotozoal Agents
        • Others (Ectoparasites, Pediculocides & miticulocides)
          • Lindane
          • Malathion
          • Pyrethrins
          • Others
      • By Route of Administration:
        • Oral
        • Injectable
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Anthelmintics
          • Benzimidazoles
          • Pyrantel
          • Niclosamide
          • Praziquantel
          • Others
        • Antiprotozoals
          • Antimalarial Drugs
            • Aminoquinolines
            • Quinoline-methanol (4-quinolinemethanols)
            • Cinchona Alkaloids
            • Biguanides
            • Sulfonamides and sulfones
            • Others
          • Other Antiprotozoal Agents
        • Others (Ectoparasites, Pediculocides & miticulocides)
          • Lindane
          • Malathion
          • Pyrethrins
          • Others
      • By Route of Administration:
        • Oral
        • Injectable
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Anthelmintics
          • Benzimidazoles
          • Pyrantel
          • Niclosamide
          • Praziquantel
          • Others
        • Antiprotozoals
          • Antimalarial Drugs
            • Aminoquinolines
            • Quinoline-methanol (4-quinolinemethanols)
            • Cinchona Alkaloids
            • Biguanides
            • Sulfonamides and sulfones
            • Others
          • Other Antiprotozoal Agents
        • Others (Ectoparasites, Pediculocides & miticulocides)
          • Lindane
          • Malathion
          • Pyrethrins
          • Others
      • By Route of Administration:
        • Oral
        • Injectable
        • Topical
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
      • Ipca Laboratories Ltd.,*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zydus Cadila
      • Merck KGaA
      • Pfizer
      • GlaxoSmithKline Plc.
      • Cipla Ltd
      • Ranbaxy Laboratories
      • Novartis AG
      • Alvizia Health Care
      • Bayer AG
      • Roche Inc.
      • Arbor Pharmaceuticals Inc.
      • Sanofi
      • AstraZeneca plc.
      • Alkem Laboratories Limited

“*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Mergers and Acquisitions
    • Pipeline Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
  4. Global Antiparasitic Drugs Market, By Drug Class, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Anthelmintics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      • Benzimidazoles
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      • Pyrantel
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      • Niclosamide
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      • Praziquantel
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      • Others
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Antiprotozoals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Antimalarial Drugs
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
            1. Aminoquinolines
              1. Introduction
              2. Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
            2. Quinoline-methanol (4-quinolinemethanols)
              1. Introduction
              2. Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
            3. Cinchona Alkaloids
              1. Introduction
              2. Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
            4. Biguanides
              1. Introduction
              2. Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million) Corticosteroids
            5. Sulfonamides and sulfones
              1. Introduction
              2. Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
            6. Others
              1. Introduction
              2. Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
          • Other Antiprotozoal Agents
              • Introduction
              • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Others (Ectoparasites, Pediculocides & miticulocides)
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Lindane
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Malathion
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Pyrethrins
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global Antiparasitic Drugs Market, By Route of Administration, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Antiparasitic Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Antiparasitic Drugs Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Ipca Laboratories Ltd.,*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zydus Cadila
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Cipla Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Ranbaxy Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Alvizia Health Care
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Roche Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Arbor Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AstraZeneca plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Alkem Laboratories Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 42 market data tables and 40 figures on "Antiparasitic Drugs Market” - Global forecast to 2027”.

Frequently Asked Questions

The global antiparasitic drugs market was valued at US$ 7,227.9 million in 2019 and is estimated to exhibit a CAGR of 5.2% between 2020 and 2027
Antiprotozoals held major market share in 2019 owing to product approvals and the rising prevalence of malaria in tropical and subtropical regions during the forecast period.
Major factors driving the growth of global antiparasitic drugs market include the increasing prevalence of parasitic diseases such as chagas disease, and research and development activities by major manufacturers.
Adverse effects of the antiparasitic drugs and high cost of these drugs is expected to restraint the growth of the antiparasitic drug market.
The Africa antiparasitic drugs market is expected to generate highest revenue during the forecast period.
Key players operating in antiparasitic drugs market are Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, Roche Inc., Arbor Pharmaceuticals Inc., Sanofi, AstraZeneca plc., and Alkem Laboratories Limited.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner